Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2018 1
2020 4
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
Xu JW, Wang BS, Gao P, Huang HT, Wang FY, Qiu W, Zhang YY, Xu Y, Gou JB, Yu LL, Liu X, Wang RJ, Zhu T, Hou LH, Wang Q. Xu JW, et al. Among authors: wang rj. Emerg Microbes Infect. 2024 Dec;13(1):2281355. doi: 10.1080/22221751.2023.2281355. Epub 2023 Dec 30. Emerg Microbes Infect. 2024. PMID: 37933089 Free PMC article. Clinical Trial.
Identification of an MiRNA-mRNA Regulatory Network in Colorectal Cancer.
Cui MF, Wu YY, Chen MY, Zhao Y, Han SY, Wang RJ, Zhang H, Fang XD. Cui MF, et al. Among authors: wang rj. Comb Chem High Throughput Screen. 2021;24(10):1736-1745. doi: 10.2174/1386207323666201110154142. Comb Chem High Throughput Screen. 2021. PMID: 33172374
Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.
Wu YF, Wei MW, Wang RJ, Guo XL, Pan HX, Gao YC, Li XL, Wang X, Ma XM, Wan P, Zhou L, Zhu YW, Li JX, Zhu FC. Wu YF, et al. Among authors: wang rj. Expert Rev Vaccines. 2023 Jan-Dec;22(1):662-670. doi: 10.1080/14760584.2023.2234997. Expert Rev Vaccines. 2023. PMID: 37432025 Free article. Clinical Trial.
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above.
Li ZP, Shi YF, Hou LH, Jin PF, Ma SH, Pan HX, Zhang JL, Shan YM, Huang HT, Wu SP, Du P, Wang X, Wang LL, Wang RJ, Wang Y, Wang XW, Zhu FC, Li JX. Li ZP, et al. Among authors: wang rj. Expert Rev Vaccines. 2022 Dec;21(12):1843-1849. doi: 10.1080/14760584.2022.2119133. Epub 2022 Sep 1. Expert Rev Vaccines. 2022. PMID: 36048417 Clinical Trial.
Epidemiological and Clinical Findings of Short-Term Recurrence of Severe Acute Respiratory Syndrome Coronavirus 2 Ribonucleic Acid Polymerase Chain Reaction Positivity in 1282 Discharged Coronavirus Disease 2019 Cases: A Multicenter, Retrospective, Observational Study.
Chen SL, Xu H, Feng HY, Sun JF, Li X, Zhou L, Song WL, Huang SS, He JL, Deng YY, Wang RJ, Fang M. Chen SL, et al. Among authors: wang rj. Open Forum Infect Dis. 2020 Sep 13;7(10):ofaa432. doi: 10.1093/ofid/ofaa432. eCollection 2020 Oct. Open Forum Infect Dis. 2020. PMID: 33123610 Free PMC article.
11 results